Latest Insider Transactions at Regeneron Pharmaceuticals, Inc. (REGN)
This section provides a real-time view of insider transactions for Regeneron Pharmaceuticals, Inc. (REGN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of REGENERON PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of REGENERON PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 23
2024
|
Christopher R. Fenimore SVP Finance & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+18.28%
|
$4,770,000
$477.66 P/Share
|
|
Jan 23
2024
|
Joseph L Goldstein Director |
SELL
Open market or private sale
|
Direct |
2,707
-29.78%
|
$2,571,650
$950.0 P/Share
|
|
Jan 23
2024
|
Joseph L Goldstein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,707
+22.95%
|
$1,691,875
$625.6 P/Share
|
|
Jan 17
2024
|
Robert E Landry EVP Finance CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
354
-1.52%
|
$329,928
$932.34 P/Share
|
|
Jan 17
2024
|
Robert E Landry EVP Finance CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
500
+2.1%
|
$189,000
$378.98 P/Share
|
|
Jan 12
2024
|
Robert E Landry EVP Finance CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
568
-2.43%
|
$527,104
$928.18 P/Share
|
|
Jan 12
2024
|
Robert E Landry EVP Finance CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
800
+3.31%
|
$302,400
$378.98 P/Share
|
|
Jan 04
2024
|
Robert E Landry EVP Finance CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
342
-1.49%
|
$313,614
$917.05 P/Share
|
|
Jan 04
2024
|
Robert E Landry EVP Finance CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
500
+2.13%
|
$189,000
$378.98 P/Share
|
|
Jan 03
2024
|
Joseph J Larosa EVP General Counsel and Secret |
SELL
Payment of exercise price or tax liability
|
Direct |
24,493
-38.25%
|
$22,337,616
$912.3 P/Share
|
|
Jan 03
2024
|
Joseph J Larosa EVP General Counsel and Secret |
BUY
Exercise of conversion of derivative security
|
Direct |
34,000
+34.68%
|
$13,566,000
$399.66 P/Share
|
|
Jan 03
2024
|
Christopher R. Fenimore SVP Finance & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,512
-18.97%
|
$6,850,944
$912.3 P/Share
|
|
Jan 03
2024
|
Christopher R. Fenimore SVP Finance & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+20.13%
|
$4,770,000
$477.66 P/Share
|
|
Jan 03
2024
|
Robert E Landry EVP Finance CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
688
-2.97%
|
$627,456
$912.3 P/Share
|
|
Jan 03
2024
|
Robert E Landry EVP Finance CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,100
+4.54%
|
$415,800
$378.98 P/Share
|
|
Jan 03
2024
|
Bonnie L Bassler Director |
SELL
Open market or private sale
|
Direct |
826
-37.41%
|
$754,964
$914.0 P/Share
|
|
Jan 03
2024
|
Bonnie L Bassler Director |
BUY
Exercise of conversion of derivative security
|
Direct |
826
+27.22%
|
$313,880
$380.95 P/Share
|
|
Jan 02
2024
|
George Yancopoulos Bd. Co-Chair, President & CSO |
SELL
Open market or private sale
|
Indirect |
33,696
-8.56%
|
$30,326,400
$900.0 P/Share
|
|
Jan 02
2024
|
Craig B. Thompson Director |
BUY
Grant, award, or other acquisition
|
Direct |
135
+22.92%
|
-
|
|
Jan 02
2024
|
Kathryn Guarini Director |
BUY
Grant, award, or other acquisition
|
Direct |
42
+12.96%
|
-
|
|
Jan 02
2024
|
David P Schenkein Director |
BUY
Grant, award, or other acquisition
|
Direct |
42
+12.96%
|
-
|
|
Jan 02
2024
|
Marion Mc Court EVP Commercial |
SELL
Open market or private sale
|
Direct |
274
-1.79%
|
$239,202
$873.91 P/Share
|
|
Jan 02
2024
|
Robert E Landry EVP Finance CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
421
-1.87%
|
$373,848
$888.34 P/Share
|
|
Jan 02
2024
|
Robert E Landry EVP Finance CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
650
+2.81%
|
$245,700
$378.98 P/Share
|
|
Jan 02
2024
|
Christine A Poon Director |
BUY
Grant, award, or other acquisition
|
Direct |
135
+5.85%
|
-
|
|
Jan 02
2024
|
Huda Y Zoghbi Director |
BUY
Grant, award, or other acquisition
|
Direct |
135
+8.9%
|
-
|
|
Jan 02
2024
|
Huda Y Zoghbi Director |
SELL
Open market or private sale
|
Direct |
1,117
-47.25%
|
$1,005,300
$900.0 P/Share
|
|
Jan 02
2024
|
Huda Y Zoghbi Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,117
+32.09%
|
$436,747
$391.92 P/Share
|
|
Jan 02
2024
|
Bonnie L Bassler Director |
BUY
Grant, award, or other acquisition
|
Direct |
135
+8.9%
|
-
|
|
Jan 02
2024
|
N Anthony Coles Director |
BUY
Grant, award, or other acquisition
|
Direct |
135
+8.84%
|
-
|
|
Jan 02
2024
|
Michael S Brown Director |
BUY
Grant, award, or other acquisition
|
Direct |
135
+8.9%
|
-
|
|
Jan 02
2024
|
Joseph L Goldstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
135
+2.07%
|
-
|
|
Jan 02
2024
|
George L Sing Director |
BUY
Grant, award, or other acquisition
|
Direct |
135
+0.51%
|
-
|
|
Jan 02
2024
|
Arthur F Ryan Director |
BUY
Grant, award, or other acquisition
|
Direct |
135
+0.73%
|
-
|
|
Jan 02
2024
|
Arthur F Ryan Director |
SELL
Open market or private sale
|
Direct |
100
-0.04%
|
$89,500
$895.69 P/Share
|
|
Dec 28
2023
|
Robert E Landry EVP Finance CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
612
-2.73%
|
$541,008
$884.88 P/Share
|
|
Dec 28
2023
|
Robert E Landry EVP Finance CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
850
+3.65%
|
$321,300
$378.98 P/Share
|
|
Dec 27
2023
|
Christopher R. Fenimore SVP Finance & CFO |
SELL
Open market or private sale
|
Direct |
2,448
-14.55%
|
$2,095,488
$856.71 P/Share
|
|
Dec 27
2023
|
Robert E Landry EVP Finance CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
542
-2.45%
|
$472,624
$872.21 P/Share
|
|
Dec 27
2023
|
Robert E Landry EVP Finance CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
750
+3.28%
|
$283,500
$378.98 P/Share
|
|
Dec 27
2023
|
Michael S Brown Director |
SELL
Open market or private sale
|
Direct |
2,049
-62.17%
|
$1,840,002
$898.0 P/Share
|
|
Dec 27
2023
|
Michael S Brown Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,049
+38.33%
|
$987,618
$482.68 P/Share
|
|
Dec 22
2023
|
Christopher R. Fenimore SVP Finance & CFO |
SELL
Open market or private sale
|
Direct |
250
-1.46%
|
$211,500
$846.27 P/Share
|
|
Dec 21
2023
|
Christopher R. Fenimore SVP Finance & CFO |
SELL
Open market or private sale
|
Direct |
1,680
-4.56%
|
$1,416,240
$843.94 P/Share
|
|
Dec 13
2023
|
Bonnie L Bassler Director |
SELL
Open market or private sale
|
Direct |
610
-32.85%
|
$530,700
$870.0 P/Share
|
|
Dec 13
2023
|
Bonnie L Bassler Director |
BUY
Exercise of conversion of derivative security
|
Direct |
610
+24.73%
|
$229,360
$376.69 P/Share
|
|
Dec 13
2023
|
Robert E Landry EVP Finance CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
723
-3.27%
|
$629,733
$871.12 P/Share
|
|
Dec 13
2023
|
Robert E Landry EVP Finance CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+4.33%
|
$378,000
$378.98 P/Share
|
|
Dec 12
2023
|
Andrew J Murphy EVP Research |
SELL
Payment of exercise price or tax liability
|
Direct |
7,657
-13.68%
|
$6,554,392
$856.71 P/Share
|
|
Dec 12
2023
|
Marion Mc Court EVP Commercial |
SELL
Payment of exercise price or tax liability
|
Direct |
5,105
-24.97%
|
$4,369,880
$856.71 P/Share
|